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Background: Despite several publications strongly advocating prophylactic antibiotics during leech therapy, and recent primary articles
shedding new light on the microbiota of leeches, many units either do not use antibiotic prophylaxis, or are continuing to use ineffective
agents. Methods: A 5-year follow-up of plastic surgery units in the United Kingdom and the Republic of Ireland was conducted in 2007 to
ascertain current practice regarding the use of prophylactic antibiotics with leech therapy. A comprehensive literature search investigated
primary research articles regarding the microbiota of leeches to update the reconstructive surgery community. Results: Despite published
evidence to support the use of prophylactic antibiotics during leech therapy, 24% of units do not use antibiotic prophylaxis and 57% of
those using antibiotics are using potentially ineffective agents. Advanced molecular genetic techniques, which allow accurate characteriza-
tion of both culturable and nonculturable microbiota of the leech digestive tract, show a wider diversity than at ﬁrst thought, with variable
antiobiotic resistance proﬁles. Conclusions: Despite infection due to leech therapy being a well known and relatively common complication,
many units are not using appropriate antibiotic prophylaxis. VC 2009 Wiley-Liss, Inc. Microsurgery 29:619–625, 2009.
Blood letting and the therapeutic use of medicinal
leeches dates back to ancient Egypt.1 Decades of reports
of leech therapy in plastic and reconstructive surgery2
and more recently the application of leeching for diverse
medical problems such as chronic pain syndromes associ-
ated with degenerative diseases3–5 have given leech ther-
apy multiple roles in modern day medicine. Their popu-
larity has indeed varied over the years, having been used
by plastic,6–9 maxillofacial,10 and other reconstructive
surgeons11,12 to aid salvage of compromised pedicled
ﬂaps,2,13 microvascular free-tissue transfers,6,14–16
venously congested digits,8,17–24 nipples,25,26 ears,27–32
lips,33,34 nasal tips,11,35 and even the penis.12 Peer-
reviewed evidence suggests that the survival of compro-
mised, venous-congested tissues is improved by early
application of a leech.36–38 The leech simulates venous
circulation until the congested tissue reestablishes venous
capillary circulation. The beneﬁts of leech therapy were
only relatively recently acknowledged with The Food and
Drug Administration of the United States approving the
use of Hirudo medicinalis as a medical device in 2004.39
While most commercial suppliers sell medicinal leeches
as H. medicinalis, a recent study revealed that the annel-
ids sold were genetically distinct from H. medicinalis and
were identiﬁed as H. verbana by Siddall et al.40 Bely
et al. encourage the increased use of ‘‘DNA Barcodes’’
such as COI gene sequences to reveal genetic variations
in leeches,41 while DeSalle et al. advocate a more cau-
tious approach until the barcode reader is reliable and the
taxonomic community is in agreement.42 Whether clariﬁ-
cation of these differences will have any medical or
microbiological importance remains to be demonstrated.
In this study, we refer to medicinal leeches as H. medici-
nalis unless the animals were speciﬁcally identiﬁed as H.
verbana. An overview of the anatomy, physiology, and
mechanisms of action of the medicinal leech relevant to
the reconstructive surgeon is summarized elsewhere.43
A high incidence of infection during and after appli-
cation of medicinal leeches has been widely reported de-
spite external decontamination. The exact incidence of
leech-associated infection associated with postoperative
use is difﬁcult to assess, with incidences ranging from
2.4% to 36.2% being reported in the literature8,36,44–46
(see Table 1). At least one clinical study has demon-
strated that limiting leech application to tissue with clear
evidence of arterial circulation while giving patients anti-
biotics effective against leech enteric ﬂora during leech
therapy can eliminate leech-related soft-tissue infection.47
Despite several publications advocating prophylactic anti-
biotics to combat leech-borne infections,7–9,44,48–52 we
were aware of many units either not using antibiotic pro-
phylaxis at all, or continuing to use inappropriate agents.
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With the knowledge of the microbiota of the leech di-
gestive tract continuing to grow, the last decade has
shown that the bacterial community is much more com-
plex than previously documented. More accurate identiﬁ-
cation and antibiotic sensitivity testing has allowed an ex-
ponential increase in relevant data regarding leech micro-
biota. A limitation of the clinical articles that previously
characterized the digestive tract microbiota of leeches
was that these studies were purely culture based. It is
now widely recognized that >99% of microbes are at
present unculturable53 and modern techniques must be
used to identify theses symbionts.
In this article we present the results of a 5-year fol-
low-up national survey of antiobiotic prophylaxis during
leech therapy and draw on the combined wisdom of both
the microbiological and plastic surgery community to dis-
cuss the implications of our ﬁndings including an up-to-
date discussion concerning leech borne infections and
appropriate evidence-based treatment.
METHODS
A telephone survey of all 62 plastic surgery units in
the United Kingdom and the Republic of Ireland was
conducted in August 2007. The names, addresses, and
phone numbers were obtained from the British Associa-
tion of Plastic, Reconstructive and Esthetic Surgeons
Website (www.bapras.co.uk). Information was obtained
from the senior sister on the Plastic and Microsurgery
ward who had ﬁrst hand experience of the use of leeches
on the unit, and was responsible for the supervision of
antibiotic administration and leech application.
Five simple questions were asked:
1. Are leeches used postoperatively by the plastic sur-
geons in your unit?
2. How many times per year on average are leeches
used?
3. Do you use antibiotics routinely postoperatively when
leeches are applied?
4. If yes: What antibiotics do you use?
5. Were there written protocols for the use of leeches?
This questionnaire was accompanied by an extensive
literature search to investigate primary research papers
regarding the microbiota of leeches and update the
reconstructive surgery community.
RESULTS
Accurate information was gained from 55 of the 62
units (89% response rate). Of these, 49 (90%) had used
leeches postoperatively in the salvage of compromised
free ﬂaps or digital replants within the last 5 years. On
average, 23 units used leeches one to ﬁve times per year,
15 units used leeches 6–10 times per year, four units
used leeches 11–15 times per year, and seven units used
leeches more than 16 times per year. Twelve units
(24.5%) did not use any antibiotic prophylaxis before or
during leech therapy. The remaining 37 units used a
range of prophylactic antibiotics routinely during leech
application including coamoxiclav, metronidazole, benzyl
penicillin, ciproﬂoxacin, and ﬂucloxacillin. Written proto-
cols concerning the use of leeches were available in 39
units (80%) and 49 units (100%) routinely kept leeches
in the hospital pharmacy overnight (see Figs. 1–4). In the
ﬁgures, ‘‘other’’ antibiotics include metronidazole, cepha-
losporins, and trimpethoprim.
DISCUSSION
This study conﬁrms that the majority of plastic sur-
gery units in the United Kingdom and Ireland use medic-
inal leeches to improve drainage from venously con-
gested tissues or extremity replants postoperatively, but
despite strong supportive evidence, 24.5% of units fail to
use any antibiotic prophylaxis. The total percentage of
units using prophylactic antibiotics has decreased from
2002 to 2007 from 92.5% to 75.5%, although the number
of units using reliably effective antibiotics such as ﬂuo-
roquinolones has improved from 22% in 2002% to 43%
in 20079 (see Fig. 4).
Leech-Borne Infection: Clinical Aspects
The leech bite is created by three jaws, each contain-
ing 60–100 pairs of cutting teeth, forming the characteris-
tic Y-shaped tri-radiate conformation 1 mm in diameter
and up to 1.5 mm in depth.54,55 These specially adapted
jaws pierce the host tissues in order to feed on blood.
The combination of local tissue damage, along with con-
tact between the oral and digestive tract ﬂora (including
both the leech crop and intestine) and the patient means
that a potential for infection exists. Although the use of
leeches in the treatment of arthritis and other medical
conditions seems to be associated with negligible risks of
infection, the venous congestion in plastic surgery
patients requiring treatment seems to lead to a localized
Table 1. Chronological Table Summarizing the Published Infection
Rates Following Leech Therapy in the Medical Literature
Number of
patients
Period
(years)
Infection
rate (%) Authors Year
30 3 20 Mercer et al.45 1987
42 Not stated 7 Lineaweaver et al.8 1992
18 5 11 De Chalain et al.36 1996
122 5 4.1 Sartor et al.46 2002
47 2 36.2 Bauters et al.44 2007
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area of immunocompromise that is more susceptible
to infection. The exact incidence of infection is difﬁcult
to assess, with incidences ranging from 2.4% to
36.2%8,36,44–46 being reported in the literature.
Extensive studies have been carried out on the sur-
face, mouth, and digestive tract microbiota of leeches,
which show Aeromonas spp. to be prominent in the resi-
dent ﬂora.36,47,48,53,56–60 The most recent of these primary
research articles was able to identify both culturable and
unculturable isolates. The most common clinical presenta-
tion of Aeromonas infection in humans is of celluli-
tis,61,62 often with a foul odor, complicated by subcutane-
ous abscess formation. In severe cases, extensive tissue
loss and septicemia has been reported.63 Aeromonas
seems to have an afﬁnity for muscle tissue, and is
capable of producing extensive proteolytic enzymes lead-
ing to a picture resembling clostridial myonecrosis with
gas production.64 Of most concern to microsurgeons is
the ability of Aeromonas to invade the walls of blood
vessels with resultant vasculitis, thrombosis, and hemor-
rhagic necrosis.65 In immunocompetent patients, surgical
site infections (SSIs) due to leech application may result
in additional antibiotic therapy, extended hospital stays,
rehospitalization, or removal of nonviable tissues.46 Cha-
lain’s meta-analysis reported on a total of 19 cases of
aeromonas infection (nine replants, three free ﬂaps, and
seven pedicled ﬂaps) with an overall salvage rate of the
tissues in the presence of infection of 31.8%, compared
with an expected salvage rate of 60–80% in noninfected
tissues.36 As one would expect, neutropenic and immuno-
compromised patients seem to be more at risk. Leech-
borne infections are by no means heterogenous in presen-
tation; delayed presentations have been recently reported
Figure 2. A bar chart showing the approximate number of cases
per year requiring leech therapy in each unit in the United Kingdom.
[Color ﬁgure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
Figure 3. A bar chart showing the percentage of United Kingdom units not using any antibiotic prophylaxis during leech therapy in 2007
compared with 2002. [Color ﬁgure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
Figure 1. A pie chart showing the percentage of units in the United
Kingdom with and without a written protocol for leech therapy.
[Color ﬁgure can be viewed in the online issue, which is available
at www.interscience.wiley.com.]
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in escharotic ﬂaps66 and a case of meningitis due to
leech-borne infection has previously been reported.67
Leech-Borne Infection: Microbiology
Since 1976 three Aeromonas genospecies (Aeromonas
hydrophila, Aeromonas veronii, and Aeromonas caviae)
have been subdivided into 14 species.68 A combination of
molecular and biochemical studies has revealed the diges-
tive tract of H. verbana contained A. veronii69,70 and not
A. hydrophila. Soft-tissue infections due to A. hydrophila
have been widely reported as a complication of leech
application but may well be due to A. veronii,58 which
has a similar clinical presentation. Apart from A. hydro-
philia, pathogens causing wound infection following Hir-
udo therapy reported in the literature include Serratia
marcescens,71 Aeromonas sobria,72 and Vibrio ﬂuvialis.73
The accurate identiﬁcation is challenging because com-
mercial identiﬁcation kits frequently misidentify the spe-
cies and such kits could report A. veronii biovar sobria as
Aeromonas sobria. The single report of Vibrio ﬂuvialis
associated infection may well have been misnamed, as
the API20E method was used for identiﬁcation purposes
and the microbe was almost certainly an Aeromonad.74
The API20E1 test (bioMerieux) was used in the older
studies to identify Aeromonas species. Although it is still
used today, it is rather imprecise when compared with
molecular genetic analysis. The test consists of a plastic
strip of 20 individual, miniaturized tests tubes (cupules)
each containing a different reagent used to determine the
metabolic capabilities, and, ultimately, the genus and spe-
cies of enteric bacteria in the family Enterobacteraceae.
Interpretation of the 20 reactions plus a separate oxidase
reaction is converted to a digital code which is compared
with a known database of bacteria.
Knowledge of the diversity, virulence, and infections
caused by Aeromonas spp. continues to increase rap-
Figure 4. A bar chart showing the percentage of units using speciﬁc antibiotic prophylaxis in 2007 compared with 2002. [Color ﬁgure can
be viewed in the online issue, which is available at www.interscience.wiley.com.]
Figure 5. E test1 results showing the susceptibility of Aeromonas
veronii to ciproﬂoxacin (top center), the complete resistance to
ampicillin (middle left), and intermediate resistance to augmentin
(amoxycillin and clavulanic acid) (bottom middle). [Color ﬁgure can
be viewed in the online issue, which is available at www.interscience.
wiley.com.]
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idly.75 Of potential clinical importance is the increasing
incidence of multidrug resistance among Aeromonas spp.
isolates that have been observed in aquaculture world-
wide. This increasing incidence of resistance is due to
the horizontal transfer of mobile genetic elements such as
plasmids and class 1 integrons.76 High levels of resistance
to ﬁrst-generation cephalosporins44 and penicillins75–77 (via
b-lactamases), tetracyclines,76 and augmentin76–79 have
been observed in studies, whereas ﬂuoroquinoles seem to be
consistently active.44,48,57,66,75–77
We performed a preliminary study to illustrate the
antibiotic resistance proﬁle of A. veronii to plastic sur-
geons considering using leeches in their practice. We
identiﬁed a leech (H. medicinalis) by comparing with
color charts80 and isolated A. veronii in the laboratory
from the leech crop using previously described tech-
niques.81 The identity of Aeromonas was conﬁrmed
using the API20E test and more accurate molecular
genetic analysis. After plating a lawn of A. veronii, three
Etest1 strips comprising predeﬁned gradients of antibi-
otic concentrations on strips of plastic were used to
determine the on-scale minimum inhibitory concentration
(MIC in lg/ml) of ciproﬂoxacin, ampicillin, and aug-
mentin. Following 48 hours of incubation, the Etest1
results showed the susceptibility of A. veronii to cipro-
ﬂoxacin (top center), the complete resistance to ampicil-
lin (middle left), and intermediate resistance to augmen-
tin (bottom middle) (see Fig. 5).
One of the limitations of this study is the lack of cul-
ture-based data from patients with infections following
leech therapy. In an ideal world, a large prospective
study would report on the clinical outcome and infection
rate following leech therapy, along with an analysis of
the microbiota and resistance proﬁles. The use of leeches
is often a last resort, unplanned, and out of hours. Per-
sonal opinions and experience of their use varies from
surgeon to surgeon. To coordinate the collection and
analysis of this data would be incredibly difﬁcult consid-
ering the diversity of units using leeches and the lack of
a centralized database.
Considering the efﬁcacy of leeches, it would be
favorable to breed a germ-free leech. Unfortunately,
H. medicinalis’s obligatory symbiotic relationship with
A. veronii seems to preclude this.53,58,81–83 Future
research could potentially be targeted toward breeding
less pathogenic genotypes which retain only the proteo-
lytic determinants with the caveat that germ-free animals
are susceptible to colonization by potentially more viru-
lent bacteria.
CONCLUSIONS
Infection due to leech therapy is a well-known com-
plication with rates of up to 36.2% in recent studies.
Many units are not using appropriate antibiotic prophy-
laxis. There is known resistance of Aeromonas species to
commonly used agents such as penicillins and augmentin.
The recommended antibiotic at the present time is cipro-
ﬂoxacin, which has favorable resistance proﬁles and good
oral bioavailability.
REFERENCES
1. Whitaker IS, Rao J, Izadi D, Butler PE. Historical article: Hirudo
medicinalis: Ancient origins of, and trends in the use of medicinal
leeches throughout history. Br J Oral Maxillofac Surg 2004;42:133–
137.
2. Derganc M, Zdravic F. Venous congestion of ﬂaps treated by appli-
cation of leeches. Br J Plast Surg 1960;13:187–192.
3. Michalsen A, Deuse U, Esch T, Dobos G, Moebus S. Effect of
leeches therapy (Hirudo medicinalis) in painful osteoarthritis of the
knee: A pilot study. Ann Rheum Dis 2001;60:986.
4. Michalsen A, Moebus S, Spahn G, Esch T, Langhorst J, Dobos GJ.
Leech therapy for symptomatic treatment of knee osteoarthritis:
Results and implications of a pilot study. Altern Ther Health Med
2002;8:84–88.
5. Michalsen A, Klotz S, Ludtke R, Moebus S, Spahn G, Dobos GJ.
Effectiveness of leech therapy in osteoarthritis of the knee: A
randomized, controlled trial. Ann Intern Med 2003;139:724–730.
6. Batchelor AG, Davison P, Sully L. The salvage of congested skin
ﬂaps by the application of leeches. Br J Plast Surg 1984;37:358–360.
7. Lineaweaver WC. Aeromonas hydrophila infections following clini-
cal use of medicinal leeches: A review of published cases. Blood
Coagul Fibrinolysis 1991;2:201–203.
8. Lineaweaver WC, Hill MK, Buncke GM, Follansbee S, Buncke HJ,
Wong RK, Manders EK, Grotting JC, Anthony J, Mathes SJ. Aero-
monas hydrophila infections following use of medicinal leeches in
replantation and ﬂap surgery. Ann Plast Surg 1992;29:238–244.
9. Whitaker IS, Izadi D, Oliver DW, Monteath G, Butler PE. Hirudo
medicinalis and the plastic surgeon. Br J Plast Surg 2004;57:348–
353.
10. Rao J, Whitaker IS. Use of Hirudo medicinalis by maxillofacial sur-
gical units in the United Kingdom: Current views and practice. Br J
Oral Maxillofac Surg 2003;41:54–55.
11. Frodel JL Jr, Barth P, Wagner J. Salvage of partial facial soft tissue
avulsions with medicinal leeches. Otolaryngol Head Neck Surg
2004;131:934–939.
12. Pantuck AJ, Lobis MR, Ciocca R, Weiss RE. Penile replantation
using the leech Hirudo medicinalis. Urology 1996;48:953–956.
13. Gideroglu K, Yildirim S, Akan M, Akoz T. Immediate use of medic-
inal leeches to salvage venous congested reverse pedicled neurocuta-
neous ﬂaps. Scand J Plast Reconstr Surg Hand Surg 2003;37:277–
282.
14. Connor NP, Conforti ML, Heisey DM, Vanderby R, Kunz D, Hartig
GK. Augmented blood removal after medicinal leech feeding in con-
gested tissue ﬂaps. J Rehabil Res Dev 2002;39:505–512.
15. Dabb RW, Malone JM, Leverett LC. The use of medicinal leeches
in the salvage of ﬂaps with venous congestion. Ann Plast Surg
1992;29:250–256.
16. Utley DS, Koch RJ, Goode RL. The failing ﬂap in facial plastic and
reconstructive surgery: Role of the medicinal leech. Laryngoscope
1998;108:1129–1135.
17. Brody GA, Maloney WJ, Hentz VR. Digit replantation applying the
leech Hirudo medicinalis. Clin Orthop Relat Res 1989;245:133–137.
18. Durrant C, Townley WA, Ramkumar S, Khoo CT. Forgotten digital
tourniquet: Salvage of an ischaemic ﬁnger by application of medici-
nal leeches. Ann R Coll Surg Engl 2006;88:462–464.
19. Gur E, Eldor A. Medicinal leeches for the salvage of a replanted
digit. Isr Med Assoc J 1999;1:62.
20. Lineaweaver WC, O’Hara M, Stridde B, Valauri FA, Buncke HJ.
Clinical leech use in a microsurgical unit: The San Francisco experi-
ence. Blood Coagul Fibrinolysis 1991;2:189–192.
Prophylactic Antibiotics and Leech Therapy 623
Microsurgery DOI 10.1002/micr
21. Shenfeld OZ. Successful use of the medicinal leech (Hirudo medici-
nalis) for the treatment of venous insufﬁciency in a replanted digit.
Isr Med Assoc J 1999;1:221.
22. Soucacos PN, Beris AE, Malizos KN, Kabani CT, Pakos S. The use
of medicinal leeches, Hirudo medicinalis, to restore venous circula-
tion in trauma and reconstructive microsurgery Int Angiol 1994;13:
251–258.
23. Tuncali D, Terzioglu A, Cigsar B, Aslan G. The value of medical
leeches in the treatment of class IIC ring avulsion injuries: Report of
2 cases. J Hand Surg [Am] 2004;29:943–946.
24. Valauri FA. Aeromonas hydrophilia infection complicating digital
replantation and revascularization. J Hand Surg [Am] 1991;16:181–
182.
25. Gross MP, Apesos J. The use of leeches for treatment of venous
congestion of the nipple following breast surgery. Aesthetic Plast
Surg 1992;16:343–348.
26. Guneren E, Erolu L, Akba H, Uysal OA, Hokelek M, Erolu C. The
use of Hirudo medicinalis in nipple-areolar congestion. Ann Plast
Surg 2000;45:679–681.
27. Cho BH, Ahn HB. Microsurgical replantation of a partial ear, with
leech therapy. Ann Plast Surg 1999;43:427–429.
28. de CT, Jones G. Replantation of the avulsed pinna: 100 percent sur-
vival with a single arterial anastomosis and substitution of leeches
for a venous anastomosis. Plast Reconstr Surg 1995;95:1275–1279.
29. Funk GF, Bauman NM, Rinehart RJ, Mankarious LA. Microvascular
replantation of a traumatically amputated ear. Arch Otolaryngol
Head Neck Surg 1996;122:184–186.
30. Hullett JS, Spinnato GG, Ziccardi V. Treatment of an ear laceration
with adjunctive leech therapy: A case report. J Oral Maxillofac Surg
2007;65:2112–2114.
31. Otto A, Schoeller T, Wechselberger G, Ohler K. [Successful ear
replantation without venous anastomosis by using leeches]. Handchir
Mikrochir Plast Chir 1999;31:98–101.
32. Talbi M, Stussi JD, Meley M. Microsurgical replantation of a totally
amputated ear without venous repair. J Reconstr Microsurg 2001;17:
417–420.
33. Holtje WJ. Successful replantation of an amputated upper lip. Plast
Reconstr Surg 1984;73:664–670.
34. Walton RL, Beahm EK, Brown RE, Upton J, Reinke K, Fudem G,
Banis J, Davidson J, Dabb R, Kalimuthu R, Kitzmiller WJ, Gottlieb
LJ, Buncke HJ. Microsurgical replantation of the lip: A multi-institu-
tional experience. Plast Reconstr Surg 1998;102:358–368.
35. Mortenson BW, Dawson KH, Murakami C. Medicinal leeches used
to salvage a traumatic nasal ﬂap. Br J Oral Maxillofac Surg 1998;
36:462–464.
36. de Chalain TM. Exploring the use of the medicinal leech: A clinical
risk-beneﬁt analysis. J Reconstr Microsurg 1996;12:165–172.
37. Hayden RE, Phillips JG, McLear PW. Leeches. Objective monitoring
of altered perfusion in congested ﬂaps. Arch Otolaryngol Head Neck
Surg 1988;114:1395–1399.
38. Lee C, Mehran RJ, Lessard ML, Kerrigan CL. Leeches: Controlled
trial in venous compromised rat epigastric ﬂaps. Br J Plast Surg
1992;45:235–238.
39. Rados C. Beyond bloodletting: FDA gives leeches a medical make-
over. FDA Consum 2004;38:9.
40. Siddall ME, Trontelj P, Utevsky SY, Nkamany M, Macdonald KS.
Diverse molecular data demonstrate that commercially available me-
dicinal leeches are not Hirudo medicinalis. Proc Biol Sci 2007;274:
1481–1487.
41. Bely AE, Weisblat DA. Lessons from leeches: A call for DNA bar-
coding in the lab. Evol Dev 2006;8:491–501.
42. DeSalle R, Egan MG, Siddall M. The unholy trinity: Taxonomy,
species delimitation and DNA barcoding. Philos Trans R Soc Lond
B Biol Sci 2005;360:1905–1916.
43. Whitaker IS, Cheung CK, Chahal CA, Karoo RO, Gulati A, Foo IT.
By what mechanism do leeches help to salvage ischaemic tissues? A
review. Br J Oral Maxillofac Surg 2005;43:155–160.
44. Bauters TG, Buyle FM, Verschraegen G, et al. Infection risk related
to the use of medicinal leeches. Pharm World Sci 2007;29:122–125.
45. Mercer NS, Beere DM, Bornemisza AJ, Thomas P. Medical leeches
as sources of wound infection. Br Med J (Clin Res Ed) 1987;
294:937.
46. Sartor C, Limouzin-Perotti F, Legre´ R, Casanova D, Bongrand MC,
Sambuc R, Drancourt M. Nosocomial Infections with Aeromonas
hydrophila from leeches. Clin Infect Dis 2002;35:E1–E5.
47. Lineaweaver WC, Furnas H, Follansbee S, Buncke GH, Whitney
TM, Canales F, Bruneteau R, Buncke HJ. Postprandial Aeromonas
hydrophila cultures and antibiotic levels of enteric aspirates from
medicinal leeches applied to patients receiving antibiotics. Ann Plast
Surg 1992;29:245–249.
48. Braga A, Lineaweaver WC, Whitney TM, Follansbee S, Buncke HJ.
Sensitivities of Aeromonas hydrophila cultured from medicinal
leeches to oral antibiotics. J Reconstr Microsurg 1990;6:135–137.
49. Hermansdorfer J, Lineaweaver W, Follansbee S, Valauri FA, Buncke
HJ. Antibiotic sensitivities of Aeromonas hydrophila cultured from
medicinal leeches. Br J Plast Surg 1988;41:649–651.
50. Kalbermatten DF, Rieger UM, Uike K, Erba P, Laifer G, Hinter-
mann B, Pierer G. [Infection with Aeromonas hydrophila after use
of leeches (Hirudo medicinalis) in a free microvascular osteo-(myo-)
cutaneous ﬂap–Suggestions for successful management]. Handchir
Mikrochir Plast Chir 2007;39:108–111.
51. Snower DP, Ruef C, Kuritza AP, Edberg SC. Aeromonas hydrophila
infection associated with the use of medicinal leeches. J Clin Micro-
biol 1989;27:1421–1422.
52. Whitaker IS, Elmiyeh B, Wright DJ. Hirudo medicinalis: The need
for prophylactic antibiotics. Plast Reconstr Surg 2003;112:1185–
1186.
53. Graf J, Kikuchi Y, Rio RV. Leeches and their microbiota: Naturally
simple symbiosis models. Trends Microbiol 2006;14:365–371.
54. Sawyer RT. Feeding and digestive system. In: Sawyer RT, editor.
Leech Biology and Behaviour. Oxford: Clarendon Press; 1986.
55. Kraemer BA, Korber KE, Aquino TI, Engleman A. Use of leeches
in plastic and reconstructive surgery: A review. J Reconstr Micro-
surg 1988;4:381–386.
56. Bickel KD, Lineaweaver WC, Follansbee S, Feibel R, Jackson R,
Buncke HJ. Intestinal ﬂora of the medicinal leech Hirudinaria manil-
lensis. J Reconstr Microsurg 1994;10:83–85.
57. Eroglu C, Hokelek M, Guneren E, Esen S, Pekbay A, Uysal OA.
Bacterial ﬂora of Hirudo medicinalis and their antibiotic sensitivities
in the Middle Black Sea Region, Turkey Ann Plast Surg 2001;47:
70–73.
58. Graf J. Symbiosis of Aeromonas veronii biovar sobria and Hirudo
medicinalis, the medicinal leech: A novel model for digestive tract
associations. Infect Immun 1999;67:1–7.
59. Graf J. Molecular requirements for the colonization of Hirudo
medicinalis by Aeromonas veronii. Prog Mol Subcell Biol 2006;
41:291–303.
60. Mackay DR, Manders EK, Saggers GC, Banducci DR, Prinsloo J,
Klugman K. Aeromonas species isolated from medicinal leeches.
Ann Plast Surg 1999;42:275–279.
61. de la Fuente AJ, Nodar GA, Touza RF, Crespo CM, Arnillas GE,
Martinez VC. [Cellulitis caused by Aeromonas hydrophila]. An Med
Interna 1999;16:635–636.
62. Fenollar F, Fournier PE, Legre R. Unusual case of Aeromonas sobria
cellulitis associated with the use of leeches. Eur J Clin Microbiol
Infect Dis 1999;18:72–73.
63. Evans J, Lunnis PJ, Gaunt PN, Hanley DJ. A case of septicaemia
due to Aeromonas hydrophila. Br J Plast Surg 1990;43:371–372.
64. Lowen RM, Rodgers CM, Ketch LL, Phelps DB. Aeromonas hydro-
phila infection complicating digital replantation and revasculariza-
tion. J Hand Surg [Am ] 1989;14:714–718.
65. Ketover BP, Young LS, Armstrong D. Septicemia due to Aeromonas
hydrophila: Clinical and immunologic aspects. J Infect Dis 1973;127:
284–290.
66. Ardehali B, Hand K, Nduka C, Holmes A, Wood S. Delayed leech-
borne infection with Aeromonas hydrophilia in escharotic ﬂap
wound. J Plast Reconstr Aesthet Surg 2006;59:94–95.
67. Ouderkirk JP, Bekhor D, Turett GS, Murali R. Aeromonas meningitis
complicating medicinal leech therapy. Clin Infect Dis 2004;38:
e36–e37.
68. Janda JM, Abbott SL. Evolving concepts regarding the genus Aero-
monas: An expanding panorama of species, disease presentations,
and unanswered questions. Clin Infect Dis 1998;27:332–344.
624 Whitaker et al.
Microsurgery DOI 10.1002/micr
69. Abbott SL, Cheung WK, Janda JM. The genus Aeromonas: Bio-
chemical characteristics, atypical reactions, and phenotypic identiﬁ-
cation schemes. J Clin Microbiol 2003;41:2348–2357.
70. Ormen O, Granum PE, Lassen J, Figueras MJ. Lack of agreement
between biochemical and genetic identiﬁcation of Aeromonas spp.
APMIS 2005;113:203–207.
71. Pereira JA, Greig JR, Liddy H, Ion L, Moss AL. Leech-borne Serra-
tia marcescens infection following complex hand injury. Br J Plast
Surg 1998;51:640–641.
72. Fenollar F, Fournier PE, Legre R. Unusual case of Aeromonas sobria
cellulitis associated with the use of leeches. Eur J Clin Microbiol
Infect Dis 1999;18:72–73.
73. Varghese MR, Farr RW, Wax MK, Chaﬁn BJ, Owens RM. Vibrio
ﬂuvialis wound infection associated with medicinal leech therapy.
Clin Infect Dis 1996;22:709–710.
74. Abbott SL, Seli LS, Catino M Jr, Hartley MA, Janda JM. Misidenti-
ﬁcation of unusual Aeromonas species as members of the genus
Vibrio: A continuing problem. J Clin Microbiol 1998;36:1103–1104.
75. Jones BL, Wilcox MH. Aeromonas infections and their treatment.
J Antimicrob Chemother 1995;35:453–461.
76. Jacobs L, Chenia HY. Characterization of integrons and tetracycline
resistance determinants in Aeromonas spp. isolated from South Afri-
can aquaculture systems. Int J Food Microbiol 2007;114:295–306.
77. Rolston KV, Ho DH, LeBlanc B, Bodey GP. Activity of newer anti-
microbial agents against Aeromonas hydrophila. Eur J Clin Micro-
biol 1986;5:454–456.
78. Motyl MR, McKinley G, Janda JM. In vitro susceptibilities of Aeromo-
nas hydrophila, Aeromonas sobria, and Aeromonas caviae to 22 antimi-
crobial agents. Antimicrob Agents Chemother 1985;28:151–153.
79. Vila J, Marco F, Soler L, Chacon M, Figueras MJ. In vitro antimi-
crobial susceptibility of clinical isolates of Aeromonas caviae, Aero-
monas hydrophila and Aeromonas veronii biotype sobria. J Antimi-
crob Chemother 2002;49:701–702.
80. Trontelj P, Utevsky SY. Celebrity with a neglected taxonomy:
Molecular systematics of the medicinal leech (genus Hirudo). Mol
Phylogenet Evol 2005;34:616–624.
81. Worthen PL, Gode CJ, Graf J. Culture-independent characterization of
the digestive-tract microbiota of the medicinal leech reveals a tripartite
symbiosis. Appl Environ Microbiol 2006;72:4775–4781.
82. Busing KH, Doll W, Freytag K. [Bacterial ﬂora of the medicinal
leech.]. Arch Mikrobiol 1953;19:52–86.
83. Kikuchi Y, Graf J. Spatial and temporal population dynamics of a
naturally occurring two-species microbial community inside the di-
gestive tract of the medicinal leech. Appl Environ Microbiol 2007;
73:1984–1991.
Prophylactic Antibiotics and Leech Therapy 625
Microsurgery DOI 10.1002/micr
